United Therapeutics Shares Rise 0.32% Amid Patent Dispute with Liquidia Trading Volume Ranked 420th in Market Activity

On August 12, 2025, United Therapeutics (UTHR) closed with a 0.32% gain, trading at a volume of $0.25 billion—a 30.73% increase from the prior day, ranking 420th in market activity. The stock’s performance reflects ongoing legal and market dynamics involving its competitor, Liquidia Therapeutics, and the latter’s newly launched drug Yutrepia.

Liquidia faces a patent infringement lawsuit from United, which alleges that Yutrepia infringes on its intellectual property related to inhaled treprostinil therapies. Both companies market drugs for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). United’s legal challenge could delay Yutrepia’s availability for ILD patients until 2042, if successful, potentially preserving United’s market dominance in the PH-ILD segment. Analyst Andreas Argyrides of Oppenheimer has highlighted the risk of patient attrition with Yutrepia, citing a 18.5% dropout rate in clinical trials compared to United’s Tyvaso, adding to the case’s strategic significance.

The legal dispute adds uncertainty to United’s competitive landscape. While Yutrepia’s early adoption has shown strong prescription numbers, the outcome of the patent battle may influence long-term market access. United’s ability to defend its IP could mitigate near-term competition and reinforce its position in the PH-ILD treatment market. However, the broader biotech sector remains volatile, with United’s stock reacting to both litigation developments and sector-wide trends.

A backtest of a strategy buying the top 500 high-volume stocks and holding for one day yielded a $2,550 profit from 2022 to the present. The approach experienced a maximum drawdown of -15.2% on October 27, 2022, underscoring the strategy’s exposure to market volatility despite overall gains.